VP, Chief Business Officer
James Wentworth, PhD, joined Transgene in 2024. Dr. Wentworth is responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategies.
He has over 15 years of experience working in the pharma and biotech industry. James was Director, Business Development and Strategy at Adaptimmune, a NASDAQ-listed biotechnology company focused on developing T-cell receptor (TCR)-based cell therapies for solid tumors. His responsibilities included strategic pharma partnering, collaborations and transactions, corporate development projects, commercial strategy development and he also led the company’s competitive intelligence function. Prior to Adaptimmune, James worked with precommercial Biotech companies at inVentiv Health (now Syneos Health) and held strategic roles at Shire, contributing to product development, post M&A integration, and managing commercial launches in European markets for ViroPharma Europe.
James holds a BSc Hons degree in Pharmacology and a PhD in Pharmacology both from the University of Bristol and an MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland.
